QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
Log in
TSE:RVX

Resverlogix Stock Forecast, Price & News

C$1.25
+0.18 (+16.82 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
C$1.12
Now: C$1.25
C$1.25
50-Day Range
C$0.75
MA: C$0.82
C$1.13
52-Week Range
C$0.35
Now: C$1.25
C$2.51
Volume171,119 shs
Average Volume68,412 shs
Market CapitalizationC$270.83 million
P/E Ratio2.20
Dividend YieldN/A
BetaN/A
Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.97 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-403-2549252

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.00 per share
Book ValueC($0.30) per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$270.83 million
Next Earnings Date9/28/2020 (Estimated)
OptionableNot Optionable
C$1.25
+0.18 (+16.82 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RVX News and Ratings via Email

Sign-up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Resverlogix (TSE:RVX) Frequently Asked Questions

How has Resverlogix's stock price been impacted by Coronavirus (COVID-19)?

Resverlogix's stock was trading at C$1.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RVX shares have increased by 21.4% and is now trading at C$1.25.
View which stocks have been most impacted by COVID-19
.

When is Resverlogix's next earnings date?

Resverlogix is scheduled to release its next quarterly earnings announcement on Monday, September 28th 2020.
View our earnings forecast for Resverlogix
.

Who are some of Resverlogix's key competitors?

What other stocks do shareholders of Resverlogix own?

Who are Resverlogix's key executives?

Resverlogix's management team includes the following people:
  • Mr. Donald J. McCaffrey, Co-Founder, Pres, CEO & Chairman
  • Mr. Aaron Bradley Cann CA, CPA, CBV, Chief Financial Officer
  • Mr. Kenneth Eugene Lebioda BA, Sr. VP of Bus. & Corp. Devel.
  • Dr. Jan O. Johansson, Sr. VP of Medical Affairs
  • Dr. Michael Sweeney, Sr. VP of Clinical Devel. (Age 58)

What is Resverlogix's stock symbol?

Resverlogix trades on the Toronto Stock Exchange (TSX) under the ticker symbol "RVX."

How do I buy shares of Resverlogix?

Shares of RVX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Resverlogix's stock price today?

One share of RVX stock can currently be purchased for approximately C$1.25.

How big of a company is Resverlogix?

Resverlogix has a market capitalization of C$270.83 million.

What is Resverlogix's official website?

The official website for Resverlogix is www.resverlogix.com.

How can I contact Resverlogix?

Resverlogix's mailing address is 300-4820 Richard Rd SW, CALGARY, AB T3E 6L1, Canada. The biotechnology company can be reached via phone at +1-403-2549252.

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.